MannKind Corporation

Bewertungs-Analyse

Über das Unternehmen

MannKind Corporation, a biopharmaceutical company, focuses on the provision of various solutions for transforming chronic disease care. It develops and commercializes treatments that address serious unmet medical needs, including diabetes, pulmonary hypertension, and fluid overload in heart failure and chronic kidney disease. It offers Afrezza inhalation powder, an inhaled insulin used to improve glycemic control in adults with diabetes; and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults. Its products also include Tyvaso DPI for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease; FUROSCIX, a furosemide injection to treat fluid buildup in patients with chronic

Trading-Daten

Ähnliche Aktien aus dem Sektor

Wo kann ich MannKind Corporation kaufen?

Vergleiche die besten Broker — niedrige Gebühren, seriöse Anbieter, reguliert.